Clinical Trial: A Study of AL8326 in Non-Small Cell Lung Cancer

U.S., Jan. 28 -- ClinicalTrials.gov registry received information related to the study (NCT06794957) titled 'A Study of AL8326 in Non-Small Cell Lung Cancer' on Jan. 30, 2024.

Brief Summary: This trial is a multicenter, single arm, open, phase IB clinical trial, designed to evaluate the preliminary efficacy and safety of AL8326 in patients with non-small cell lung cancer (NSCLC) who relapsed or progressed after multi line treatment and failed standard treatment.

Study Start Date: May 19, 2022

Study Type: INTERVENTIONAL

Condition: Non-small Cell Lung Cancer

Intervention: DRUG: AL8326 tablets

10mg/tablet;Oral administration, once daily.

Recruitment Status: ACTIVE_NOT_RECRUITING

Sponsor: Advenchen Laboratories, LLC

Published by HT D...